Accordingly, BRAFV600 mutation is an important factor to guide CM treatment, and BRAF and MEK inhibitors (BRAFi/MEKi) represent the best therapeutic strategy for BRAF‐mutated CM patients so far. Here, BRAF is linked to cutaneous mastocytosis.